Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jin T. E. Lim"'
Autor:
Andrew K. Joe, Jin T. E. Lim, Muneyuki Masuda, Masahito Shimizu, I. Bernard Weinstein, Masumi Suzui
Publikováno v:
Clinical Cancer Research. 12:3478-3484
In previous studies, we found that sulindac sulfide and exisulind (sulindac sulfone, Aptosyn) cause growth inhibition, arrest cells in the G1 phase of the cell cycle, and induce apoptosis in human breast cancer cell lines. These effects were associat
Autor:
Julia H. Hayes, Kyriakos P. Papadopoulos, Masumi Suzui, Atsuko Deguchi, I. Bernard Weinstein, Jin T. E. Lim, Masahito Shimizu, Danhua Xiao
Publikováno v:
Clinical Cancer Research. 10:6710-6721
Hepatoma is one of the most frequently occurring cancers worldwide. However, effective chemotherapeutic agents for this disease have not been developed. Acyclic retinoid, a novel synthetic retinoid, can reduce the incidence of postsurgical recurrence
Autor:
Masumi Suzui, Masahito Shimizu, Muneyuki Masuda, Jin T. E. Lim, Naoki Yoshimi, I. Bernard Weinstein
Publikováno v:
Molecular Cancer Therapeutics. 3:309-316
Acyclic retinoid (ACR), a novel synthetic retinoid, has recently been demonstrated by us to inhibit the in vitro growth of human hepatoma cells, and this effect was associated with decreased expression of cell cycle-related molecules. These results,
Autor:
Edward J. Kennelly, Danhua Xiao, Thomas Pertel, Fredi Kronenberg, Masahito Shimizu, Jin T. E. Lim, Masumi Suzui, I. Bernard Weinstein, Colette Seter, Paiboon Nuntanakorn, Linda Saxe Einbond
Publikováno v:
Breast Cancer Research and Treatment. 83:221-231
The purpose of this study was to determine whether black cohosh contains constituents that inhibit the growth of human breast cancer cells, and therefore might eventually be useful in the prevention or treatment of breast cancer. Black cohosh rhizome
Autor:
Atsuko Deguchi, Jin T. E. Lim, Masumi Suzui, I. Bernard Weinstein, Jae-Won Soh, Muneyuki Masuda
Publikováno v:
Journal of Experimental Therapeutics and Oncology. 2:350-359
In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and rela
Autor:
Paul H. Gross, I. Bernard Weinstein, Gerhard Sperl, Han Li, Gary A. Piazza, E. K.-H. Han, Thomas Delohery, Rifat Pamukcu, Klaus Brendel, Hirofumi Yamamoto, Tyler S. Finn, Ralph Buttyan, Jin T. E. Lim
Publikováno v:
Biochemical Pharmacology. 58:1097-1107
We examined the activity of two metabolites of sulindac (a nonsteroidal anti-inflammatory drug), sulindac sulfide and sulindac sulfone (exisulind, Prevatec), and a novel highly potent analog of exisulind (CP248) on a series of human prostate epitheli
Autor:
I. Bernard Weinstein, Jin T. E. Lim, Hisataka Moriwaki, Levy Kopelovich, Masahito Shimizu, Atsuko Deguchi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(7)
Purpose: (−)-Epigallocatechin gallate (EGCG) inhibits activation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2) and multiple downstream signaling pathways in cancer cell lines. In this study we co
Autor:
Masumi, Suzui, Masahito, Shimizu, Muneyuki, Masuda, Jin T E, Lim, Naoki, Yoshimi, I Bernard, Weinstein
Publikováno v:
Molecular cancer therapeutics. 3(3)
Acyclic retinoid (ACR), a novel synthetic retinoid, has recently been demonstrated by us to inhibit the in vitro growth of human hepatoma cells, and this effect was associated with decreased expression of cell cycle-related molecules. These results,
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(3)
We described recently the growth inhibitory effects of the novel compound acyclic retinoid (ACR) in human hepatoma cell lines (M. Suzui et al., Cancer Res., 62: 3997–4006, 2002). In this study we examined the cellular and molecular effects of ACR o
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(13)
In recent studies, we found that sulindac sulfide (SS), exisulind, CP248, and CP461 induce growth inhibition and apoptosis in a series of human prostate cancer cell lines, irrespective of cyclooxygenase expression, p53 mutations, or bcl-2 overexpress